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A B S T R A C T
The aim of this study was to determine if dysplastic endocervical cells (EC) posses a
neoplastic potential as precursor lesions to adenocarcinoma in situ (AIS). The malig-
nant potential was determined by assessing the ploidy status and proliferative activity
by flow cytometry and c-myc expression by immunohistochemistry. The studied parame-
ters were assessed separately in morphologically normal, dysplastic and malignant EC.
The 2 test showed significant association of malignant EC with aneuploidy (p=0.008)
and high proliferative activity (p=0.042). Since one third of the dysplastic EC are also
aneuploid and show high mitotic activity, they probably have malignant potential as
well. The dysplastic EC showed a significant association with c-myc oncogene expression
(p=0.028). Our results indicate the existence of pre-malignant glandular lesions, while
the immunohistochemical detection of c-myc protooncogene could be helpful in detection
of EC with malignant potential, even without any dysplastic morphological changes.
Key words: precursor lesions, cervical adenocarcinoma, ploidy, S-phase, c-myc
oncogene
Introduction
During the past three decades, the
spectrum of endocervical glandular lesions
has attracted increasing attention because
of the absolute increase in the prevalence
of invasive primary adenocarcinoma (ACA)
of the uterine cervix all over the world1–3.
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Unlike primary ACA of the cervix, the
incidence of squamous cell carcinomas
(SCC) has decreased4–8. A reduced mor-
bidity and mortality of cervical SCC is
due to early detection of its precursor le-
sions (cervical intraepithelial lesions –
CIN grade II/III), for which there well-es-
tablished morphological criteria exist9,10.
The existence of precursor lesions of
adenocarcinoma in situ (AIS) or invasive
ACA is still a controversial topic11–14. Some
authors believe that there are recogniz-
able pre-neoplastic glandular lesions, while
others think that morphological evidence
is not sufficient to support the existence
of pre-malignant lesions culminating in
AIS12,14. Although the histological abnor-
malities of endocervical cells (EC) are fre-
quent findings adjacent to AIS and inva-
sive ACA, their potential pre-cancerous
nature should be examined by objective
parameters11,14,15. Aneuploidy, higher mi-
totic activity and over expression of the
c-myc oncogene are nowadays well docu-
mented features of malignant cells15–19.
The EC histomorphological abnormalities
vary within a broad spectrum, with fea-
tures intermediate between those of AIS
and the normal endocervical epithelium15.
In order to include all cytologically trans-
formed EC the term dysplasia is used15,20.
According to present insights into the
carcinogenesis, neoplastic transforma-
tion is a long-term process from normal to
malignant cell, during which many mo-
lecular mechanisms occur, leading after
certain period of time to genomic instabil-
ity and phenotypic variation20.
The final step in the process of malig-
nant transformation of the cell is the ac-
cumulation of many genetic events that
lead to DNA damage manifested as quan-
titative changes in the DNA content and
everlasting proliferation16,20–22. Aneuploi-
dy represents an abnormal amount of
DNA23. The period of the cell cycle during
which cells are in preparation for cell di-
vision is called the S phase23. Ploidy sta-
tus and S-phase fraction of certain cell
populations are easily detected by flow
cytometry. Consequently, in the malig-
nant cell population in which the process
of carcinogenesis has been completed, the
DNA content is abnormal (aneuploidy
and high S-phase fraction) displaying also
visible malignant morphological changes
that are easily recognized by a patholo-
gist17.
In attempt to detect carcinomas in the
earliest phase of their development many
new molecular studies simultaneously and
continuously analyze the genetic events
during the process of proliferation in both
normal and malignant cells18,19,24,25. These
studies discovered that the overexpres-
sion of the c-myc oncogene is the first crit-
ical genetic event in the process of carci-
nogenesis18,19.
The c-myc gene controls cell growth
and proliferation of each type of human
cell26. During the process of proliferation,
the normal, non-neoplastic cells showed
the c-myc gene product localized in the
nucleus. Due to its short half-life of 15–20
minutes, it desintegrated very soon27,28.
In cells, which suffered malignant trans-
formation triggered by overexpression of
c-myc oncogen, the enormous production
of oncoproteins accumulated in the cyto-
plasm of the transformed cells27,28. There-
fore, the earliest manifestation of malig-
nant transformation of the cell without
visible morphological changes could be an
increased cytoplasmatic expression of the
c-myc oncoprotein.
The aim of this study was to deter-
mine the DNA content (ploidy and pro-
liferative status) and the expression of
the c-myc oncogene in the dysplastic EC,
and to compare them results with the
DNA content and the c-myc expression in
the morphologically normal or malignant
EC of AIS or ACA. The idea was to deter-
mine whether dysplastic EC have fea-
tures different from normal cells, which
would indicate their malignant potential.
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Samples and Methods
Sample selection
Serial sections of the cervices stained
with hematoxylin and eosin (H&E) were
obtained from 49 patients who under-
went cone biopsy or hysterectomy because
of a previously diagnosed AIS or primary
invasive ACA of the cervix by punch bi-
opsy. Only one representative slide was
chosen from each patient, showing simul-
taneously the presence of the morphologi-
cally normal endocervical glands and the
areas of endocervical glandular dysplasia
adjacent to the area of malignant EC in
AIS or invasive ACA (Figure 1).
Morphological criteria
In order to be able to study the biologi-
cal behavior of the endocervical dysplas-
tic cells, the morphological criteria had
first to be established. The minimum his-
tological criteria for dysplasia were ap-
plied, knowing the definite morphological
definitions of the normal and malignant
EC15,17.
According to many different histolo-
gical descriptions of the dysplastic EC
found in literature12–14 and in our per-
sonal experience based on observation,
we established well-defined criteria for
dysplasia. The most obvious abnormal
changes are nuclear. The nuclei are slight-
ly enlarged, elongated and often cigar
-shaped, with some variations in size and
shape. Hyperchromasia is usually a pro-
minent feature. Mitotic figures are ab-
sent or very rare. The epithelium may
also show the loss of polarity, so that the
nuclei are haphazardly arranged in rela-
tion to the basement membrane and the
luminal surface. These changes are clear-
ly different from the single, basal, small,
uniform nucleus of normal EC or from the
enlarged and elongated nuclei with fre-
quent mitosis and prominent pseudostra-
tification.
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Fig. 1. The detail of one representative histological slide. In the middle (arrow), there are three
glands with the dysplastic EC between the normal endocervical glands on the right and the malig-
nant endocervical epithelium of AIS on the left.
Collecting samples for flow cytometry
analysis
In order to determine the ploidy status
and proliferative activity of the normal,
dysplastic and malignant EC from the
chosen samples with diagnosed AIS or in-
vasive ACA, a different marker encircled
the representative areas on each chosen
slide. Another section from paraffin block
was cut in order to get similar slide. From
that unstained slide, the foci at the match-
ing location with marked areas on H&E
stained slide were microdissected in three
pieces to get normal, dysplastic and ma-
lignant cell populations separately and
then prepared for the flow cytometry ana-
lysis.
For the purpose of identifying the plo-
idy status and S-phase standard of the
normal EC, a control group of 20 tissue
samples with morphologically normal EC
from the patients undergoing hysterec-
tomy for uterine leiomyoma was analyzed.
The control tissues with the normal
EC, as well as the microdissected tissues
with the normal, dysplastic, and malig-
nant endocervical epithelium from the
representative samples, were separately
processed for flow cytometry performed
by FACSCalibur (Becton Dickinson, San
Jose, CA, SAD) using the computer pro-
grams –CellquestTM and ModFit LTTM
and the method described by Leers et al29.
The flow cytometer measured the DNA
content (ploidy and S-phase) of each dis-
aggregated nucleus in the cell suspension
and plotted results as a histogram show-
ing relation between DNA content (x-axis)
and total cell count (y-axis). All histo-
grams that have only one peak represent
the DNA diploid population.
The definition of the DNA aneuploid
cell populations requires the presence of
two distinct peaks in the histogram23.
The results of the ploidy status of the nor-
mal EC from the control group are shown
in Table 1.
The assessment of the S-phase frac-
tion of the dysplastic and malignant EC
was possible after we determined the
standard S-phase of the normal endo-
cervical epithelium in the control cervical
tissues. The percentage of the normal EC
ranged from 0.48% to 3.42% (Table 1). Ac-
cording to this S-phase standard of nor-
mal cervical tissue, all studied dysplastic
and malignant EC were divided into two
groups: the first group of cells which
S-phase fraction was lower than 3.42%
(S1) and considered normal, and the sec-
ond group of cells, which S-phase fraction
was higher than 3.42% and considered to
have higher mitotic activity (S2).
Immunohistochemical staining
From the same paraffin blocks with
chosen samples, several more 3 µm sec-
tions were cut for immunohistochemical
staining with the anti-c-myc monoclonal
antibodies (Serotec, Oxford, UK). To de-
tect the reaction product the immunohis-
tochemical staining used the avidin-bio-
tin-peroxidase complex technique with
3.3'-diaminobenzidene as the chromoge-
ne. Anti-c-myc antibody was used at 1:50
dilution after antigen retrieval in EDTA
at pH 8.0, and microwaved for 15 minutes
at room temperature.
Because the different cellular localiza-
tion of c-myc product was first noticed
and well documented in normal colon epi-
thelium, adenomas and adenocarcinomas
of the colon, the samples of the colon car-
cinoma associated with an accumulation
of cytoplasmic c-myc oncoprotein were
used as positive control27,28. The normal
mucosal cells adjacent to the colon carci-
noma showed no or only nuclear staining
(data not shown).
For the negative control the same pro-
cedure was used, but for the omission of
the primary antibody.
The positive c-myc oncoprotein over-
expression in studied EC was considered
when diffuse brown cytoplasmic staining
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was seen (Figure 2). Table 1 also shows
the results of the anti-c-myc antibody
immunohistochemical staining in the
control group with the morphologically
and clinically normal cervical tissues.
Statistical analysis
2 test was performed using a comput-
erized statistical package (SPSS 7.0 for
Windows) to determine whether an asso-
ciation between the dysplastic and malig-
nant EC exists. The level of significance
was defined as p<0.05.
Results
Table 1 shows the flow cytometry and
the immunohistochemistry data for the
control group, enabling us to compare the
results of the flow cytometry analysis of
normal, dysplastic and malignant EC from
studied tissues (Table 2).
Ploidy status
All 20-control samples with normal EC
were diploid.
In the experimental samples (N=49),
almost all normal EC were diploid (98%),
whereas one third of dysplastic EC were
aneuploid.
In the majority of cases, the malignant
EC were characterized by aneuploidy
(59.2%), but the rest were diploid despite
malignant morphological features.
2-test showed a significant associa-
tion between the malignant EC and ane-
uploidy (2=6.944; p=0.008; Table 3).
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TABLE 1
RESULTS OF FLOW CYTOMETRY AND IMMUNOHISTOCHEMISTRY ANALYSIS ON 20 CONTROL
CERVIX TISSUE SAMPLES CONTAINING NORMAL ENDOCERVICAL EPITHELIUM
No. of patients
Flow cytometry Immunohistochemistry:
c-myc oncoproteinPloidy S-phase (%)
1. Diploid 2.87 –
2. Diploid 0.48 –
3. Diploid 1.96 –
4. Diploid 1.63 –
5. Diploid 3.42 +
6. Diploid 1.28 –
7. Diploid 1.33 –
8. Diploid 2.27 –
9. Diploid 1.58 –
10. Diploid 2.05 –
11. Diploid 1.87 –
12. Diploid 1.07 –
13. Diploid 2.64 –
14. Diploid 2.15 –
15. Diploid 1.97 –
16. Diploid 2.58 –
17. Diploid 1.94 –
18. Diploid 1.05 –
19. Diploid 0.91 –
20. Diploid 2.53 –
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Fig. 2. Immunohistochemical demonstration of c-myc oncogene product in morphologically differ-
ent EC. C-myc oncoprotein positivity is obvious in the cytoplasm of the endocervical gland with
morphologically clear dysplastic EC (upper left corner). In morphologically normal EC of the gland
located in the down right corner of the pictur c-myc oncoprotein expression is lacking.
TABLE 2
RESULTS OF FLOW CYTOMETRY AND IMMUNOHISTOCHEMISTRY ANALYSIS OF 49





Dysplastic Malignant Dysplastic Malignant Normal Dysplastic Malignant
1. diploid diploid normal normal negative positive negative
2. aneuploid aneuploid high high negative positive negative
3. diploid diploid normal high negative positive positive
4. diploid diploid normal normal negative negative positive
5. aneuploid aneuploid high high positive positive positive
6. aneuploid aneuploid normal high negative negative negative
7. aneuploid aneuploid high high negative negative negative
8. aneuploid aneuploid high high negative positive negative
9. aneuploid aneuploid normal high negative negative negative
10. aneuploid aneuploid normal high negative negative negative
11. diploid aneuploid high high positive positive positive
12. aneuploid aneuploid high high negative positive positive
13. aneuploid aneuploid high normal negative positive positive
14. diploid diploid normal normal negative positive positive
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Dysplastic Malignant Dysplastic Malignant Normal Dysplastic Malignant
15. aneuploid aneuploid high high positive positive negative
16. aneuploid aneuploid normal normal negative positive positive
17. diploid diploid normal normal negative positive negative
18. diploid aneuploid high high negative positive positive
19. diploid diploid normal normal negative positive positive
20. diploid diploid normal normal negative negative positive
21. diploid diploid normal normal negative negative positive
22. diploid aneuploid normal high negative positive positive
23. diploid aneuploid normal high negative negative negative
24. diploid diploid normal normal negative positive positive
25. diploid aneuploid normal normal negative positive positive
26. aneuploid aneuploid high normal negative positive negative
27. diploid diploid normal normal negative positive positive
28. diploid diploid normal high negative positive negative
29. aneuploid aneuploid normal high negative positive positive
30. diploid aneuploid normal high negative negative positive
31. diploid diploid normal normal negative positive positive
32. diploid diploid normal normal negative positive negative
33. diploid diploid normal normal negative positive positive
34. diploid aneuploid high high negative positive positive
35. aneuploid aneuploid high high negative positive negative
36. diploid diploid normal normal negative positive positive
37. diploid aneuploid normal high negative positive negative
38. aneuploid aneuploid high high positive positive positive
39. diploid diploid normal high negative positive positive
40. diploid aneuploid normal high negative positive positive
41. diploid aneuploid normal normal negative positive positive
42. diploid diploid normal normal negative negative negative
43. diploid aneuploid high high positive positive negative
44. diploid aneuploid high high negative positive negative
45. diploid diploid normal normal negative positive negative
46. aneuploid aneuploid high high negative positive positive
47. diploid diploid normal normal negative positive positive
48. diploid aneuploid high high negative positive negative
49. diploid diploid normal normal negative positive positive
* Ploidy status was assessed by flow cytometry of dysplastic and malignant EC epithelium;
** S-phase of dysplastic and malignant EC epithelium was normalizedto control group and
considered normal (1  3.42%) or high (> 3.42%);
*** c-myc oncoprotein expression in normal, dysplastic and malignant EC cells
TABLE 2 Continued
S-phase fraction
Among the dysplastic EC, 65.3% dis-
played normal and 34.7% high prolifera-
tive activity. The malignant EC of AIS or
ACA had 44.9% samples with normal and
55.1% with high mitotic activity.
2-test showed a significant associa-
tion between the malignant EC and higher
proliferative activity (2=4.125; p=0.042;
Table 4).
As one third of dysplastic cells were
aneuploid and had a high mitotic activity
it may be expected they have a malignant
potential.
Expression of the c-myc oncogene
Only one sample of the normal en-
docervical epithelium from the control
group showed a mild positive cytoplasmic
c-myc oncoprotein expression.
In the glands with the normal endo-
cervical epithelium from the experimen-
tal cervical tissue, the c-myc oncoprotein
was expressed in only 10.2% samples.
The proportion of the c-myc positive cells
was increased in the morphologically
changed EC. In the endocervical glands
with the morphologically obvious dysplas-
tic changes c-myc oncoprotein expression
was positive in 79.6% samples whereas
only 59.2% of malignant EC samples were
positive.
2-test showed a significant associa-
tion between the dysplastic endocervical
cells and the expression of the c-myc on-
coprotein (2=4.804; p=0.028; Table 5).
As the c-myc oncoprotein is the mar-
ker of neoplastic transformation of the
cell, its cytoplasmic expression confirms
the malignant potential of dysplastic EC.
Discussion
Frequent histological findings of dys-
plastic endocervical glands in the border
areas between the normal and malignant
glands awakened our suspicions as to
their pre-malignant potential. The main
problem was that the dysplastic endocer-
vical epithelium forms a wide histological
spectrum between the AIS and the nor-
mal endocervical epithelium and we, on
the other hand, had no standard morpho-
logical definitions applicable to such a
histological spectrum.
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TABLE 3
PLOIDY OBTAINED BY FLOW CYTOMETRY
ANALYSIS IN THE DYSPLASTIC AND MALIG-
NANT ENDOCERVICAL EPITHELIUM FROM 49
PATIENTS WITH AIS OR INVASIVE ACA OF
THE CERVIX
EC cells Diploid Aneuploid Total
Dysplastic 33 16 49
Malignant 20 29 49
Total 53 45 98
2 = 6.944; p=0.0084
TABLE 4
THE S-PHASE DATA OBTAINED BY THE FLOW
CYTOMETRY ANALYSIS IN THE DYSPLASTIC
AND MALIGNANT ENDOCERVICAL EPITHE-
LIUM FROM 49 PATIENTS WITH AIS OR
INVASIVE ACA OF THE CERVIX
EC cells S1 S2 Total
Dysplastic 32 17 49
Malignant 22 27 49
Total 54 44 98




IN DYSPLASTIC AND MALIGNANT ENDOCER-
VICAL EPITHELIUM FROM 49 PATIENTS WITH






Dysplastic 10 39 49
Malignant 20 29 49
Total 30 68 98
2 = 4.803; p=0.0284
According to present knowledge, the
biological behavior of the dysplastic cells
is unpredictable, because some of them
may be included in potentially reversible
processes, while the others may progress
to AIS15.
The existence of the aneuploid nuclear
content, a higher mitotic activity, and the
overexpression of cytoplasmatic c-myc
oncoprotein among the spectrum of the
endocervical dysplastic cells, helped us to
discover the biological nature of some of
them. The results of our study show that
one third of the studied dysplastic popu-
lation has a DNA aneuploidy and a higher
S-phase, the well-documented and statis-
tically significant markers of malignant
cells15–19. These data, obtained by the flow
cytometric analysis, support the hypothe-
sis about the existence of the precancer-
ous lesions to AIS. Although we used
standardized procedures to prepare and
analyze the control and representative
samples, as well as to analyze and inter-
pret the cytometry data, we must stress
that the flow cytometry technique has an
important limitation. It consists in the in-
ability to detect loss of 3–5% of the DNA
content23. That is the reason that certain
number of aneuploid cells is counted au-
tomatically as diploid. Thus, even among
our malignant cell populations with a def-
inite malignant transformation, almost
over 40% of them were diploid and have a
normal mitotic activity. Therefore, the
measurement of the DNA content by
means of flow cytometry provides support
for the hypothesis regarding the existen-
ce of the precursor lesions to AIS, but the
clinical utility for their recognition is not
satisfactory.
Many studies showed that the over-
expression of the c-myc oncoprotein was
involved in the initial phase of the malig-
nant transformation, when the cell has
no chromosomal aberrations yet, but shows
very subtle or none morphological chan-
ges18,19. Immunohistochemical methods
on the histological samples that simulta-
neously showed the spectrum of the en-
docervical changes ranging from the nor-
mal to dysplastic and malignant cells
were used in order to determine whether
the differences in expression of that onco-
protein exist in cells of different morphol-
ogy. Our results show that almost 80% of
the dysplastic EC had the cytoplasmic
c-myc oncoprotein expression and defini-
tively confirm the hypothesis of their ma-
lignant significance. It is possible that,
the rest of the morphologically dysplastic
cells without the c-myc expression have
reactive changes without the neoplastic
potential. Our results also support the
hypothesis about importance of the c-myc
oncogene activation in carcinogenesis. Ten
percent of the morphologically normal EC
and almost 60% of the morphologically
malignant cells (with lower expression
than in the dysplastic cells) support the
hypothesis that the c-myc expression is
important as one of the switches that
turn the normal cell into the pre-malig-
nant one, while afterwards, its impor-
tance diminishes19.
Our data showed that some endocer-
vical dysplastic cells have an aneuploid
DNA content and a high S-phase, as well
as cytoplasmatic expression of the c-myc
oncoprotein, supporting the role of the
EC dysplasia in the evolution of AIS.
But since the flow cytometry and immu-
nohistochemical methods have some limi-
tations in detection the malignant poten-
tial of the cell, additional, more accurate
molecular techniques should be used.
Our findings that a pathologist can
not morphologically distinguish the dys-
plastic endocervical epithelium with ma-
lignant potential from the reactive, rever-
sible dysplastic epithelium, emphasize
the clinical importance of the detection of
c-myc oncoprotein in the cell cytoplasm
using the immunohistochemical method.
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MALIGNI POTENCIJAL DISPLASTI^NOG ENDOCERVIKALNOG
EPITELA U ODNOSU NA STANJE PLOIDIJE, FRAKCIJOM S-FAZE
I EKSPRESIJOM C-MYC
S A @ E T A K
Cilj ove studije bio je odrediti imaju li displasti~ne endocervikalne stanice (ES) neo-
plasti~ni potencijal kao prekursorne lezije za adenokarcinoma in situ (AIS). Maligni
potencijal odre|en je procjenom stanja ploidije i proliferativne aktivnost putem cito-
metrije te c-myc ekspresije imunohistokemijski. Ispitivani parametri procijenjeni su
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zasebno u morfolo{ki normalnim, displasti~nim te malignim endocervikalnim stani-
cama. 2 test je pokazao zna~ajnu povezanost malignih EC s aneuploidijom (p=0,008) i
visokom proliferativnom aktivnosti (p=0,042). Kako je jedna tre}ina displasti~nih EC
tako|er aneuploidna i pokazuje visoku mitotsku aktivnost, one vjerojatno tako|er ima-
ju maligni potencijal. Displasti~ne EC su pokazale zna~aju povezanost s c-myc onko-
genom ekspresijom (p=0,028). Prikazani rezultati upu}uju na postojanje pre-malignih
glandularnih lezija, dok imunohistokemijska detekcija c-myc protoonkogena mo`e biti
od pomo}i u detekciji EC s malignim potencijalom i to onda kada displasti~ne morfo-
lo{ke promjene nisu prisutne.
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